. 2012 Apr 29;171(9):1339–1348. doi: 10.1007/s00431-012-1726-4

Table 4.

Consensus on the treatment of children and adolescents with types I and II HAE-C1-INH

	Therapy for acute attacks			Short-term and long-term prophylaxis
	Peripheral and urogenital	Abdominal	Facial and laryngeal	Short-term and long-term prophylaxis
“Wait and see”	+/−	+/−	−	n/a
pdC1-INH concentrate	+	+	+	+^a
Recombinant C1-INH concentrate, Icatibant and Ecallantide^b,c	−	−	−	−
Attenuated androgens^d	−	−	−	−
Tranexamic acid	−	−	−	−

n/a not applicable, +/− depending on the intensity

^aOf the two available products, only Cinryze is approved for long-term prophylaxis

^bRecombinant C1-INH concentrate, ecallantide, and icatibant are currently not approved for children and adolescents in Europe. Studies in children and adolescents are required

^cNo approval for ecallantide in Europe

^dAttenuated androgens are not approved in Germany, in Austria not for children